New drug for mild asthma! AstraZeneta has been approved ® the ® Drug Administration to treat mild asthma in adults and adolescents over 12 years of age!

AstraZeneta has announced that it has been officially approved by China's National Drug Administration® (NMPA®) for anti-inflammatory treatment for mild asthma patients in adults and adolescents over 12 years of age.
It's worth noting that The ®Dubao® is the first combination therapy approved in China for the treatment of mild asthma (i.e., inhalation of glucosin/long-acting beta-2-subject astrogen (ICS/LABA) combination therapy) and will provide a full-scale management program for patients with mild, moderate and severe asthma.
previously, the ® had ® approved for moderate to severe asthma remission and maintenance treatment.
Xinhua®Dubao ® (Budined Fumotro Inhaled Powder Mist II.) is the national preferred inhalation of glucosin/long-acting beta2 subject astration (ICS/LABA) for the treatment of asthma patients of all severity for full asthma control.
As a compound preparation for Budinide (ICS) and Formotro (LABA), Budinaid Fumotro Inhaled Powder Mist II. Approved for the treatment of asthma or chronic obstructive pulmonary disease in about 120 countries and listed in China in 2004.
is also the only asthma treatment co-agent to be included in the World Health Organization (WHO) Standard List of Essential Medicines (2019 edition) and the National Essential Medicines Directory (2018 edition).
, there are more than 48 million asthma patients in China, of whom mild asthma accounts for more than 75% of the total population, and most of them are not timely and accurate diagnosis and treatment.
, up to 30 to 40 percent of people with mild asthma are likely to have severe acute seizures.
to effectively control symptoms and reduce the risk of acute onset, early anti-inflammatory interventions for mild asthma are important.
the SYGMA study, published in the New England Journal of Medicine, includes SYGMA1 and SYGMA2.
results confirm that for patients with poor control after receiving quick-acting inhalation bronchial dilators (SABA) only on demand, or for receiving low-dose inhaled corticosteroids or white triene recipient antagonists (LCR) plus on-demand use In patients who were controlled after the effective inhalation bronchial dilator, anti-inflammatory relief treatment of Budined Fumotro inhaled powder mist II was more effective in follow-up treatment than on-demand treatment of mild asthma with quick-acting beta2-subject agonists.
Professor Zhou Xin, vice chairman of the 10th Committee of the Chinese Medical Association's Respiratory Credit Committee and head of the Respiratory Science Department at Shanghai First People's Hospital, said: "At present, mild asthma is showing an increasing trend, but due to mild symptoms, not enough attention has been paid.
approval of budine de fumotro inhalation powder mist II. New adaptations provides patients and doctors with another treatment plan to meet the clinical needs of a wide range of patients with mild, moderate and severe asthma.
”